Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Blood|September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study GroupFrank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
The New England Journal of Medicine|June 9, 2016
Genomic Classification and Prognosis in Acute Myeloid LeukemiaElli Papaemmanuil, Moritz Gerstung, Lars Bullinger, et al.
Cancer Cell|April 14, 2010
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemiaShujun Liu, Lai-Chu Wu, Jiuxia Pang, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Blood|March 22, 2014
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialStephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, et al.
Blood|September 8, 2018
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLFelicitas Thol, Razif Gabdoulline, Alessandro Liebich, et al.
Pageof 8